Endo International | ENDP - Gross Profit On Sales


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview

Endo International

Endo International reported $347.82M in Gross Profit on Sales for its fiscal quarter ending in March of 2023.


Gross Profit On Sales Change
ANI Pharmaceuticals ANIP:US USD 69.08M 11.17M
Bristol-Myers Squibb BMY:US USD 8.77B 114M
Eli Lilly LLY:US USD 5.33B 420.4M
Endo International ENDP:US USD 347.82M 10.83M
Hikma Pharmaceutical HIK:LN USD 642M 19M
Horizon Pharma HZNP:US USD 623.5M 77.75M
Merck & Co MRK:US USD 11.14B 1.15B
Novartis NOVN:VX USD 9.38B 215M
Pacira PCRX:US USD 111.32M 1.28M
Patterson Companies PDCO:US USD 342.96M 14.87M
Perrigo PRGO:US USD 413.8M 31.2M
Pfizer PFE:US USD 13.26B 1.21B
Phibro Animal Health PAHC:US USD 75.54M 1.84M
Revance Therapeutics RVNC:US USD 33.16M 6.75M
Supernus Pharmaceuticals SUPN:US USD 130.3M 14.07M
Takeda 4502:JP JPY 646.38B 114.19B
Teva Pharmaceutical Industries Ltd TEVA:IT USD 1.65B 454M
Zoetis ZTS:US USD 1.45B 57M